Identification of TRE-130 as Reversible Inhibitor of Pan-EGFR Mutants while Sparing EGFR Wild-Type Activity

被引：2
作者：
Duggirala, Krishna Babu [1 ,2 ]
Choe, Hyeonjeong [1 ]
Jeon, Byeong Uk [1 ]
Jung, Myoung Eun [1 ]
Go, Areum [1 ]
Lim, Byungho [1 ]
Park, Chaewon [3 ]
Yoon, Jiyeun [3 ]
Chae, Chong Hak [1 ]
Cho, Byoung Chul [3 ]
Choi, Gildon [1 ,2 ]
Lee, Kwangho [1 ,2 ]
机构：
[1] Korea Res Inst Chem Technol, Bio & Drug Discovery Div, Daejeon 34114, South Korea
[2] Univ Sci & Technol, Med Chem & Pharmacol, Daejeon 34113, South Korea
[3] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul 03722, South Korea
来源：
BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2019年 / 40卷 / 12期
关键词：
EGFR T790M/C797S; Kinases; NSCLC; Diaminopyrimidines; Sulfonylurea; LUNG-CANCER; RESISTANCE; MUTATIONS; AZD9291; POTENT;
D O I：
10.1002/bkcs.11886
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
[No abstract available]
引用
收藏
页码：1222 / 1225
页数：4
相关论文
共 19 条
  • [1] [Anonymous], 2017, SCHRO REL 2017 1 MAE
  • [2] Design of compounds that increase the absorption of polar molecules
    Bowe, CL
    Mokhtarzadeh, L
    Venkatesan, P
    Babu, S
    Axelrod, HR
    Sofia, MJ
    Kakarla, R
    Chan, TY
    Kim, JS
    Lee, HJ
    Amidon, GL
    Choe, SY
    Walker, S
    Kahne, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (22) : 12218 - 12223
  • [3] L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib
    Callegari, D.
    Ranaghan, K. E.
    Woods, C. J.
    Minari, R.
    Tiseo, M.
    Mor, M.
    Mulholland, A. J.
    Lodola, A.
    [J]. CHEMICAL SCIENCE, 2018, 9 (10) : 2740 - 2749
  • [4] Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment
    Choe, Hyeonjeong
    Jeon, Byeong Uk
    Jung, Myoung Eun
    Jeon, Moon-Kook
    Shin, Inji
    Cho, Byoung Chul
    Choi, Gildon
    Chae, Chong Hak
    Lee, Kwangho
    [J]. BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2017, 38 (11): : 1353 - 1357
  • [5] EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
    Ercan, Dalia
    Choi, Hwan Geun
    Yun, Cai-Hong
    Capelletti, Marzia
    Xie, Ting
    Eck, Michael J.
    Gray, Nathanael S.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3913 - 3923
  • [6] Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
    Fassunke, Jana
    Mueller, Fabienne
    Keul, Marina
    Michels, Sebastian
    Dammert, Marcel A.
    Schmitt, Anna
    Plenker, Dennis
    Lategahn, Jonas
    Heydt, Carina
    Braegelmann, Johannes
    Tumbrink, Hannah L.
    Alber, Yannic
    Klein, Sebastian
    Heimsoeth, Alena
    Dahmen, Ilona
    Fischers, Rieke N.
    Scheffler, Matthias
    Ihle, Michaela A.
    Priesner, Vanessa
    Scheel, Andreas H.
    Wagener, Svenja
    Kron, Anna
    Frank, Konrad
    Garbert, Katia
    Persigehl, Thorsten
    Puesken, Michael
    Haneder, Stefan
    Schaaf, Bernhard
    Rodermann, Ernst
    Engel-Riedel, Walburga
    Felip, Enriqueta
    Smit, Egbert F.
    Merkelbach-Bruse, Sabine
    Reinhardt, H. Christian
    Kast, Stefan M.
    Wolf, Juergen
    Rauh, Daniel
    Buettner, Reinhard
    Sos, Martin L.
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [7] Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
    Huang, Wei-Sheng
    Liu, Shuangying
    Zou, Dong
    Thomas, Mathew
    Wang, Yihan
    Zhou, Tianjun
    Romero, Jan
    Kohlmann, Anna
    Li, Feng
    Qi, Jiwei
    Cai, Lisi
    Dwight, Timothy A.
    Xu, Yongjin
    Xu, Rongsong
    Dodd, Rory
    Toms, Angela
    Parillon, Lois
    Lu, Xiaohui
    Anjum, Rana
    Zhang, Sen
    Wang, Frank
    Keats, Jeffrey
    Wardwell, Scott D.
    Ning, Yaoyu
    Xu, Qihong
    Moran, Lauren E.
    Mohemmad, Qurish K.
    Jang, Hyun Gyung
    Clackson, Tim
    Narasimhan, Narayana I.
    Rivera, Victor M.
    Zhu, Xiaotian
    Dalgarno, David
    Shakespeare, William C.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (10) : 4948 - 4964
  • [8] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    Kim, Dong-Wan
    Planchard, David
    Ohe, Yuichiro
    Ramalingam, Suresh S.
    Ahn, Myung-Ju
    Kim, Sang-We
    Su, Wu-Chou
    Horn, Leora
    Haggstrom, Daniel
    Felip, Enriqueta
    Kim, Joo-Hang
    Frewer, Paul
    Cantarini, Mireille
    Brown, Kathryn H.
    Dickinson, Paul A.
    Ghiorghiu, Serban
    Ranson, Malcolm
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) : 1689 - 1699
  • [9] Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
    Kobayashi, Yoshihisa
    Mitsudomi, Tetsuya
    [J]. CANCER SCIENCE, 2016, 107 (09) : 1179 - 1186
  • [10] Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition
    Lee, Seoyoung
    Kim, Jiwon
    Duggirala, Krishna Babu
    Go, Areum
    Shin, Inji
    Cho, Byoung Chul
    Choi, Gildon
    Chae, Chong Hak
    Lee, Kwangho
    [J]. BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2018, 39 (07): : 895 - 898
12